Discriminating promiscuous from target-specific autoantibodies in COVID-19.
Autoantibodies
Autoimmunity
Autoreactivity
COVID-19
SARS-CoV-2
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
31
01
2023
received:
13
10
2022
accepted:
27
02
2023
medline:
19
5
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Diverse autoantibodies were suggested to contribute to severe outcomes of COVID-19, but their functional implications are largely unclear. ACE2, the SARS-CoV-2 receptor and a key regulator of blood pressure, was described to be one of many targets of autoantibodies in COVID-19. ACE2 in its soluble form (sACE2) is highly elevated in the blood of critically ill patients, raising the question of whether sACE2:spike complexes induce ACE2 reactivity. Screening 247 COVID-19 patients, we observed elevated sACE2 and anti-ACE2 IgG that were poorly correlated. Interestingly, levels of IgGs recognizing ACE2, IFNα2, and CD26 strongly correlated in severe COVID-19, with 15% of sera showing polyreactivity versus 4.1% exhibiting target-directed autoimmunity. Promiscuous autoantibodies failed to impair the activity of ACE2 and IFNα2, while only specific anti-IFNα2 IgG compromised cytokine function. Our study suggests that the detection of autoantibodies in COVID-19 is often attributed to a promiscuous reactivity, potentially misinterpreted as target-specific autoimmunity with functional impact.
Identifiants
pubmed: 36856018
doi: 10.1002/eji.202250210
doi:
Substances chimiques
Autoantibodies
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
Immunoglobulin G
0
Banques de données
DRKS
['DRKS00021688']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2250210Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H. H., Zhang, Y., Dorgham, K. et al., Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020. 370: eabd4585.
Zuo, Y., Estes, S. K., Ali, R. A., Gandhi, A. A., Yalavarthi, S., Shi, H., Sule, G. et al., Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020. 12: eabd3876.
Xiao, M., Zhang, Y., Zhang, S., Qin, X., Xia, P., Cao, W., Jiang, W. et al., Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol. 2020. 72: 1998-2004.
Blagova, O., Varionchik, N., Zaidenov, V., Savina, P. and Sarkisova, N., Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur. J. Immunol. 2021. 51: 893-902.
Wang, E. Y., Mao, T., Klein, J., Dai, Y., Huck, J. D., Jaycox, J. R., Liu, F. et al., Diverse functional autoantibodies in patients with COVID-19. Nature 2021. 595: 283-288.
Chang, S. E., Feng, A., Meng, W., Apostolidis, S. A., Mack, E., Artandi, M., Barman, L. et al., New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 2021. 12: 5417.
Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G. and Shoenfeld Y., The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021. 20: 102792
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q. et al., Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020. 581: 215-220.
Arthur, J. M., Forrest, J. C., Boehme, K. W., Kennedy, J. L., Owens, S., Herzog, C., Liu, J. et al., Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021. 16: e0257016.
Rodriguez-Perez, A. I., Labandeira, C. M., Pedrosa, M. A., Valenzuela, R., Suarez-Quintanilla, J. A., Cortes-Ayaso, M., Mayán-Conesa, P. et al., Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J. Autoimmun. 2021. 122: 102683
Casciola-Rosen, L., Thiemann, D. R., Andrade, F., Trejo-Zambrano, M. I., Leonard, E. K., Spangler, J. B., Skinner, N. E. et al., IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022. 7: e158362.
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M. et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000. 87: E1-E9.
Benigni, A., Cassis, P. and Remuzzi, G., Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol. Med. 2010. 2: 247-257.
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P. et al., Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005. 436: 112-116.
Lambert, D. W., Yarski, M., Warner, F. J., Thornhill, P., Parkin, E. T., Smith, A. I., Hooper, N. M. et al., Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 2005. 280: 30113-30119.
Shulla, A., Heald-Sargent, T., Subramanya, G., Zhao, J., Perlman, S. and Gallagher, T., A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 2010. 85: 873-882.
Fagyas, M., Fejes, Z., Sütő, R., Nagy, Z., Székely, B., Pócsi, M., Ivády, G. et al., Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients. Int. J. Infect. Dis. 2022. 115: 8-16.
WHO. WHO R&D blueprint novel coronavirus COVID-19 Therapeutic Trial Synopsis 2020a. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.
McMillan, P., Dexhiemer, T., Neubig, R. R. and Uhal, B. D., COVID-19-a theory of autoimmunity against ACE-2 explained. Front Immunol. 2021. 12: 582166.
Alkharsah, K. R., Aljaroodi, S. A., Rahman, J. U., Alnafie, A. N., Dossary, R. A., Aljindan, R. Y., Alnimr, A. M. et al., Low levels of soluble DPP4 among Saudis may have constituted a risk factor for MERS endemicity. PLoS One. 2022. 17: e0266603.
Akbil, B., Meyer, T., Stubbemann, P., Thibeault, C., Staudacher, O., Niemeyer, D., Jansen, J. et al., Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies. J. Clin. Immunol. 2022. 42: 1111-1129.
Tiller, T., Tsuiji, M., Yurasov, S., Velinzon, K., Nussenzweig, M. C., Wardemann, H., Autoreactivity in human IgG+ memory B cells. Immunity 2007. 26: 205-213.
Mouquet, H. and Nussenzweig, M. C., Polyreactive antibodies in adaptive immune responses to viruses. Cell. Mol. Life Sci. 2012. 69: 1435-1445.
Mouquet, H., Scheid, J. F., Zoller, M. J., Krogsgaard, M., Ott, R. G., Shukair, S., Artyomov, M. N. et al., Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010. 467: 591-595.
Stano, A., Leaman, D. P., Kim, A. S., Zhang, L., Autin, L., Ingale, J., Gift, S. K. et al., Dense array of spikes on HIV-1 virion particles. J. Virol. 2017. 91: e00415- e00417.
Ke, Z., Oton, J., Qu, K., Cortese, M., Zila, V., McKeane, L., Nakane, T. et al., Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 2020. 588: 498-502.
Kurth, F., Roennefarth, M., Thibeault, C., Corman, V. M., Müller-Redetzky, H., Mittermaier, M., Ruwwe-Glösenkamp, C. et al., Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). Infection 2020. 48: 619-626.
Group, R. C., Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L. et al., Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2020. 384: 693-704.
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S. et al., 2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019. 71: 1400-1412.
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K. et al., A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020. 26: 1033-1036.
McCoy, L. E., Quigley, A. F., Strokappe, N. M., Bulmer-Thomas, B., Seaman, M. S., Mortier, D., Rutten, L. et al., Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 2012. 209: 1091-1103.
Kallewaard, N. L., Corti, D., Collins, P. J., Neu, U., McAuliffe, J. M., Benjamin, E., Wachter-Rosati, L. et al., Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 2016. 166: 596-608.
Xiao, F. and Burns, K. D., Measurement of angiotensin converting enzyme 2 activity in biological fluid (ACE2). Hypertension 2017. 1527: 101-115.